Pompe Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pompe Disease stocks.

Pompe Disease Stocks Recent News

Date Stock Title
May 21 SNY ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
May 21 SNY Sanofi teams up with Formation Bio, OpenAI on AI-driven drug development
May 21 SNY Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
May 20 SNY Sanofi: Information concerning the total number of voting rights and shares - April 2024
May 20 SNY Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
May 20 SNY Shah Capital ends campaign against Novavax board after Sanofi deal
May 20 FOLD Amicus Therapeutics: Too Cheap At Under $10 A Share
May 19 BMRN Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)
May 19 SNY This Stock Just More Than Doubled in 1 Day: Is It a Buy?
May 18 SNY Is Novavax Stock a Buy?
May 18 BMRN 4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
May 17 SNY The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
May 17 BMRN Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
May 17 SNY Could Novavax Become the Next Moderna?
May 16 SNY Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
May 16 SNY Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16 SNY If You'd Invested $10,000 in Novavax a Year Ago, This Is How Much You'd Have Now
May 16 BMRN Third Point top buy and sells in Q1
May 15 BMRN BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15 BMRN Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170
Pompe Disease

Glycogen storage disease type II, also called Pompe disease, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. It is the only glycogen storage disease with a defect in lysosomal metabolism, and the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.
The build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and the nervous system.

Browse All Tags